Specific immunotherapy with neuraminidase-modified leukemic cells: experimental and clinical trials.
The data presented establish the therapeutic effectiveness of immunotherapy with neuraminidase-treated allogeneic myeloblasts in combination with sustaining chemotherapy in patients with acute myelocytic leukemia. The in vivo and in vitro immunologic tests indicate normal immunocompetence in patients receiving immunotherapy versus control patients treated with chemotherapy alone. These findings correlate well with the improved duration of remission as the direct result of the immunotherapy.
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007109:Immunity; D007111:Immunity, Cellular; D007167:Immunotherapy; D007939:Leukemia L1210 / Q000628:therapy; D007942:Leukemia, Experimental / Q000276:immunology / Q000628:therapy*; D007951:Leukemia, Myeloid / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D008806:Mice, Inbred AKR; D008811:Mice, Inbred DBA; D009439:Neuraminidase / Q000494:pharmacology*; D012882:Skin Tests
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D009439:Neuraminidase